(Q48225077)

9 February 2018

title

The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas (English)

1 reference

9 February 2018

1

A Colao

1 reference

9 February 2018

S Lastoria

2

1 reference

9 February 2018

D Ferone

3

1 reference

9 February 2018

P Varrella

4

1 reference

9 February 2018

P Marzullo

5

1 reference

9 February 2018

R Pivonello

6

1 reference

9 February 2018

G Cerbone

7

1 reference

9 February 2018

W Acampa

8

1 reference

9 February 2018

M Salvatore

9

1 reference

9 February 2018

G Lombardi

10

1 reference

9 February 2018

publication date

1 March 1999

1 reference

9 February 2018

Journal of Endocrinological Investigation

published in

1 reference

9 February 2018

volume

22

1 reference

9 February 2018

issue

3

1 reference

9 February 2018

page(s)

176-183

1 reference

9 February 2018

https://api.crossref.org/works/10.1007%2FBF03343538

1 reference

Specific somatostatin receptors on human pituitary adenoma cell membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343538

The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343538

Pituitary imaging using a labelled somatostatin analogue in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343538

Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343538

Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343538

[111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343538

In VivoDetection of Somatostatin Receptors in Patients with Functionless Pituitary Adenomas by Means of a Radioiodinated Analog of Somatostatin ([123I]SDZ 204–090)*

21 January 2018

1 reference

12 December 2020

Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy

1 reference

12 December 2020

Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical 'cure'

1 reference

12 December 2020

The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadenomas

1 reference

12 December 2020

Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide

1 reference

12 December 2020

Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands.

1 reference

12 December 2020

High Density of Somatostatin Receptors in Pituitary Tumors from Acromegalic Patients

1 reference

12 December 2020

Predicting the effects of long-term medical treatment in acromegaly. At what cost? For what benefits?

1 reference

12 December 2020

Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro

1 reference

12 December 2020

Prediction of efficacy of octreotide therapy in patients with acromegaly.

1 reference

12 December 2020

Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas

1 reference

12 December 2020

Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: evidence for different tumor subclasses

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03343538

1 reference

9 February 2018

1 reference

9 February 2018